---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-167512"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:56:45.999123+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kyverna's miv-cel meets all endpoints in KYSA-8 SPS trial; median T25FW improvement 46% (p=0.0003)

## Summary
- Single-dose miv-cel achieved statistically significant improvements across all primary and secondary endpoints at Week 16.
- 81% of patients achieved ≥20% improvement in T25FW; 67% of walking-aid users no longer needed assistance.
- All 26 patients discontinued chronic immunotherapies through last follow-up; no high-grade CRS or ICANS observed.
- Company plans to submit BLA for miv-cel in SPS; data also support potential in myasthenia gravis.
- Natural history study of 153 SPS patients showed minimal improvement with current treatments, underscoring unmet need.

## SEC filing metadata
- accession: 0001193125-26-167512
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312526167512/0001193125-26-167512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312526167512/kytx-20260421.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-167512
- JSON: https://secwatch.observer/filing/0001193125-26-167512.json
- Plain text: https://secwatch.observer/filing/0001193125-26-167512.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.